Evidence map›Paper›PMID 31221124›Full record

ArticleBMC cancer2019

Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.

Haiwei Wang, Xinrui Wang, Liangpu Xu, Ji Zhang, Hua Cao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Haiwei WangFujian Key Laboratory for Prenatal Diagnosis and Birth Defect, Fujian Provincial Maternity and Children's Hospital, affiliated hospital of Fujian Medical University, FuZhou, FuJian, China. hwwang@sibs.ac.cn.
Xinrui WangFujian Key Laboratory for Prenatal Diagnosis and Birth Defect, Fujian Provincial Maternity and Children's Hospital, affiliated hospital of Fujian Medical University, FuZhou, FuJian, China.
Liangpu XuFujian Key Laboratory for Prenatal Diagnosis and Birth Defect, Fujian Provincial Maternity and Children's Hospital, affiliated hospital of Fujian Medical University, FuZhou, FuJian, China.
Ji ZhangState Key Laboratory for Medical Genomics, Shanghai Institute of Hematology, Rui-Jin Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Hua CaoFujian Key Laboratory for Prenatal Diagnosis and Birth Defect, Fujian Provincial Maternity and Children's Hospital, affiliated hospital of Fujian Medical University, FuZhou, FuJian, China. caohua69@fjmu.edu.cn.
Fujian Medical University · CNNational Health and Family Planning Commission · CNShanghai Jiao Tong University · CN

Funding

Fujian Provincial Maternity and Children's Hospital YCXB 18-10 and YCXM 19-04
6 · The paper itself

Abstract

backgroundProgrammed cell death protein 1(PD-1) blocking antibodies have been used to enhance immunity in solid tumors and achieve durable clinical responses with an acceptable safety profile in multiple types of cancer. However, only a subset of patients could benefit from PD-1 blockade therapy. Prognostic information including PD-1 ligand (PD-L1) expression, IFN-γ expression signature, tumor mutational burden, and microsatellite instability (MSI) have been evaluated for patients who are selected to receive immune checkpoint therapeutic treatment. Yet the relationship of those biomarkers in determining immune checkpoint therapy is largely unknown.

methodsImmune-profiles of MSI subtype colon cancer were identified from integrating published MSI associated gene expression data. The enriched pathways and transcription factors were analyzed by GSEA assay. The infiltrations of immune cell types into MSI subtype colon cancer tissues were determined by CIBESORT assay.

resultsIn the MSI subtype colon cancer patients, PD-L1, IFN-γ and IFN-γ associated genes are highly expressed. And all those genes are favorable effects in colon cancer progress. In addition, we find that Wnt-β-catenin and TGFβ signaling pathways which are two important factors inhibiting PD-1 checkpoint blockade therapy are negatively related with MSI status. We also identify that the immune-profiles in MSI subtype colon cancer are contributed by M1 macrophage infiltration in the tumor environment.

conclusionsOur results provide the detailed underlying mechanisms of MSI subtype cancer patients are sensitive to PD-1 checkpoint blockade.

Indexed as

Microsatellite InstabilityBiomarkers, TumorCell Line, TumorColonic NeoplasmsGene ExpressionHumansImmunotherapyInterferon-gammaInterferon Regulatory Factor-1MacrophagesMutL Protein Homolog 1PhthalazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesPrognosisProgrammed Cell Death 1 ReceptorBiomarkers, TumorInterferon-gammaInterferon Regulatory Factor-1IRF1 protein, humanMLH1 protein, humanMutL Protein Homolog 1PARP1 protein, humanPARP2 protein, humanPDCD1 protein, humanPhthalazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesProgrammed Cell Death 1 ReceptortalazoparibTransforming Growth Factor betaIFN-γM1 macrophage cellsMSIPD-1TGFβ signaling pathwayWnt-β-catenin signaling pathway

Identifiers

PMID31221124
PMCPMC6585086
OpenAlexW2949866757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.